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Anti-neutrophil cytoplasm antibodies (ANCA) are associated with small vessel vasculitides
(AASV) affecting the lungs and kidneys. Structured clinical assessment using the Birm-
ingham Vasculitis Activity Score and Vasculitis Damage Index should form the basis of a
treatment plan and be used to document progress, including relapse. Severe disease with
organ or life threatening manifestations needs cyclophosphamide or rituximab, plus high
dose glucocorticoids, followed by lower dose steroid plus azathioprine, or methotrexate.
Additional plasmapheresis is effective for very severe disease, reducing dialysis depen-
dence from 60 to 40% in the first year, but with no effect on mortality or long-term renal
function, probably due to established renal damage. In milder forms of ANCA-associated
vasculitis, methotrexate, leflunomide, or mycophenolate mofetil are effective. Mortality
depends on initial severity: 25% in patients with renal failure or severe lung hemorrhage;
6% for generalized non-life threatening AASV but rising to 30–40% at 5 years. Mortality
from GPA is four times higher than the background population. Early deaths are due to
active vasculitis and infection. Subsequent deaths are more often due to cardiovascular
events, infection, and cancer. We need to improve the long-term outcome, by controlling
disease activity but also preventing damage and drug toxicity. By contrast, in large vessel
vasculitis where mortality is much less but morbidity potentially greater, such as giant cell
arteritis (GCA) andTakayasu arteritis, therapeutic options are limited. High dose glucocorti-
coid results in significant toxicity in over 80%. Advances in understanding the biology of the
vasculitides are improving therapies. Novel, mechanism based therapies such as rituximab
in AASV, mepolizumab in eosinophilic granulomatosis with polyangiitis, and tocilizumab in
GCA, but the lack of reliable biomarkers remains a challenge to progress in these chronic
relapsing diseases.
Keywords: vasculitis, cyclophosphamide, rituximab, ANCA, glucocorticoid, plasmapheresis, methotrexate,
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INTRODUCTION
The systemic vasculitides are a complex set of overlapping con-
ditions whose natural history has been significantly modified by
current therapies but continue to challenge patients and clinicians.
We expect survival in over 90% (compared to over 90% mortality
untreated) in the first year; about 70% with small vessel vasculi-
tis survive up to 5 years, giving a mortality ratio of 2.6 (95% CI
2.2–3.1) compared to background (1, 2).
In large vessel vasculitis, mortality is low (3) but morbidity is
high. In giant cell arteritis (GCA), visual loss occurs in up to 35%
(4). In Takayasu arteritis, ischemic claudication of limbs and great
vessels can require surgical reconstruction (5).
Current therapies minimize systemic and local inflammation
and can preserve organ function. Immunosuppressive agents are
combined with supportive management, which includes: com-
pensating for organ dysfunction (e.g., treating hypertension or
providing dialysis); dealing with or preventing comorbidity, which
might arise from treatment (e.g., infection, steroid related osteo-
porosis, or cataract); worsening of pre-existing comorbidity (e.g.,
worsening of ischemic heart disease or obesity); or development
of new comorbidity.
We need to ensure that we identify what we are actually treating
so that we tailor the choice of treatment at the right dose and at
right time for each individual.
WHAT ARE WE TREATING?
Making an accurate diagnosis of the type of vasculitis is an impor-
tant part of treatment choices. Figure 1 illustrates a typical plan
of management for patients with vasculitis. There are no diagnos-
tic criteria for the vasculitides; Chapel Hill Consensus Conference
definitions are widely applied (6). Classification criteria for vas-
culitis are currently problematic (7) and research is underway to
improve them (8). However, the diagnostic label is not enough.
The patient’s status should include assessment of disease sever-
ity and the context in which the disease occurs in individuals.
Table 1 outlines the immunosuppressive therapies used to manage
vasculitis.
The range of diseases encompassed includes small, medium,
and large vessel vasculitis; small and medium vessel diseases are
grouped together because the standard treatment approaches are
very similar; however, they are starting to diversify as we develop
more targeted agents.
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FIGURE 1 | Managing systemic vasculitis.
For patients with a virus associated vasculitis, treatment of the
virus is a prerequisite to controlling disease. Polyarteritis nodosa
(PAN) related to hepatitis B (HBV-PAN), a typical form of PAN,
is characterized by the absence of glomerulonephritis and the
absence of anti-neutrophil cytoplasm antibodies (ANCA); relapses
are rare, and never occur once viral replication has stopped and
seroconversion has occurred (18). Eradication of hepatitis B is part
of the management for HBV-PAN (18).Combining an anti-viral
drug with plasmapheresis facilitates seroconversion and prevents
the development of long-term hepatic complications of HBV.
The incidence of HBV-PAN has decreased 10-fold as a result
of improved blood safety and vaccination campaigns (19). In a
study of 80 patients with HBV-PAN given anti-viral therapy plus
immunosuppression, 5% relapsed and 30% died compared with
14.3% relapses and 48.6% deaths among 35 patients treated with
immunosuppression alone. Patients who seroconverted achieved
complete remission and did not relapse.
Unfortunately, the eradication of hepatitis C has been more
problematic; patients with cryoglobulinaemic vasculitis may con-
tinue to require ongoing anti-viral therapy. Combination anti-
viral therapy is more effective, as shown in a study of cryoglobuli-
naemic vasculitis; 69% of 23 cases treated with a combination of
pegylated interferon alpha, ribavirin, and a protease inhibitor had
achieved undetectable viral loads and a good clinical response in
the majority including complete remission in 57% (20).
In small vessel vasculitis associated with ANCA, these anti-
bodies are intricately involved in the pathogenesis (21). The role
of conventional immunosuppressive agents remains important.
Cyclophosphamide is the gold standard for multi-system small
vessel vasculitis (22, 23); for less aggressive forms of disease, there
is a potential role for leflunomide (24), methotrexate (25) or in
one small series, high dose intravenous azathioprine (13). Whilst
small open label studies of tumor necrosis factor (TNF) inhibition
have suggested benefit (26) in disease control and improvement
in abnormal endothelial dysfunction, a large randomized placebo
controlled trial of etanercept, a TNF receptor protein, has shown
no benefit in patients with GPA; in fact these patients had an
increased risk of malignancy, which may in part have related
to the inclusion of patients previously exposed to large doses
of cyclophosphamide (27). Direct targeting of B cell production
of antibody is an effective therapy for many but not all patients
(28–30).
For patients with large vessel vasculitis such as GCA or Takayasu
arteritis, the primary treatment is glucocorticoids, but as we iden-
tify disease mechanisms, we should be able to use targeted ther-
apies, avoiding the use of high doses of steroids, which result in
very significant toxicity in over 80% (31).
MECHANISM SPECIFIC VS. GLOBAL IMMUNOSUPPRESSION
Immunosuppressive therapy results in global effects on the
immune system, which can be both good and bad. Glucocorti-
coids produce a rapid improvement in all types of vasculitis by
genomic effects on the cytosolic and more rapid non-genomic
effects on the membrane bound glucocorticoid receptor (32), but
these effects are short lived in small vessel vasculitis. By contrast,
most patients experience significant steroid toxicity (over 80% for
GCA) and this relates to the total steroid load (31). It is important
to tailor the dose of steroids, often used together with an immuno-
suppressive agent (see Table 1), to minimize the harm, while still
controlling disease.
Specific targeting of inflammatory immune mechanism in vas-
culitis is increasingly practical as we identify the molecular path-
ways that are primarily responsible for the disease. The role of
complement in ANCA-associated vasculitis (33) has led to the
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Table 1 | Immunosuppressive therapies used to treat systemic vasculitis.
Drug Phase of
therapy
Dose Indication/comments Common adverse
effects
NON-BIOLOGICAL IMMUNOSUPPRESSIVETHERAPIES USEDTOTREAT SYSTEMICVASCULITIS
Glucocorticoids Induction and
maintenance
Varies but usually required at high initial
dose (0.75–1 mg/kg/day) tapering after
4 weeks with good disease control
For GCA and Takayasu arteritis, this may
be the only immunosuppression given.
For most other forms of systemic
vasculitis, additional immunosuppressive
agents are mandatory. Increasingly, we
recognize the adverse effects of
glucocorticoid therapy and the aim is to
minimize their use
Weight gain
Hyperglycemia
Mood swings
Easy bruising
Infection risk
Cataracts
Hypertension
Osteoporosis
Cushing’s syndrome
Subsequent reduction of steroids is
more rapid in the first 4–6 months
(e.g., 5–15 mg per day reduction every
1–2 weeks), then much slower (e.g.,
1 mg every 1–2 months) for large
vessel vasculitis; in small and medium
vessel vasculitis, because the patient
is usually also managed with another
immunosuppressive agent,
glucocorticoid reduction protocols can
be more aggressive
In small and medium vessel
multi-system disease such as GPA,
MPA, EGPA, and PAN, glucocorticoid
therapy remains essential to the
management, except for Kawasaki
disease where it is rarely used
Pulse high dose intravenous
methylprednisolone (500–1000 mg)
may be indicated for organ or life
threatening manifestations, but the
evidence base for its use is poor
Cyclophosphamide Induction Usually given intravenously as high
dose intermittent pulses of
15 mg/kg/dose on 6–10 occasions,
2–3 weeks apart. Oral pulse therapy is
feasible and delivers higher level of
active metabolites (due to first pass
metabolism in liver to active
compound)
Most forms of small vessel ANCA
vasculitis, some patients with PAN and
some with large vessel vasculitis require
cyclophosphamide
Cytopenias
Nausea and vomiting
Diarrhea
Hair loss
Teratogenesis (avoid in
pregnancy)
Hemorrhagic cystitis
Rituximab is increasingly used as an
alternative for patients with ANCA
vasculitis who have failed
cyclophosphamide or in whom
cyclophosphamide is contraindicated
Long-term risk of infertility and
malignancy (especially bladder
carcinoma) relate to cumulative
dose life-time exposure
especially above 35 g
Continuous daily oral
cyclophosphamide is also effective but
the cumulative dose is much higher
after 6 months compared to pulse
therapy
Plasmapheresis Induction Additional to conventional
immunosuppression. No standard
volume of exchange. A typical regimen
would be to use between 7 and 10
exchanges (4 l each) in first 10 days of
induction therapy (9). It is not clear
which method of plasmapheresis
(centrifugation or filtration) is superior
Evidence from one large randomized
controlled trial suggests that additional
plasmapheresis is renal sparing (10), but
a follow up study of the same patient
group suggested that the benefit did not
last (11), suggesting that plasmapheresis
may not be effective if used in patients
with established kidney scarring
Increased risk of sepsis
especially if combined with
cyclophosphamide
Potential risk of transmission of
viral infection if using infected
blood products
A smaller study of 32 patients with GPA
with 5-year follow up showed that
plasmapheresis plus cyclophosphamide
and glucocorticoids followed by
ciclosporin maintenance therapy was
effective in patients with a creatinine of
>250µmol/l at baseline (12)
(Continued)
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Table 1 | Continued
Drug Phase of
therapy
Dose Indication/comments Common adverse
effects
Avoid plasmapheresis shortly after
administration of other IV therapies
(otherwise they are removed)
Methotrexate Induction or
maintenance
15–25 mg/week oral or sc Can be used as effective induction
therapy for non-organ or non-life
threatening ANCA vasculitis. It provides
some additional benefit in control of
GCA. Avoid use in significant renal
impairment
Nausea
Diarrhea
Mouth ulcers
Hair loss
Cytopenia
Liver dysfunction
Leflunomide Induction or
maintenance
10–40 mg/day This drug is used for inflammatory
arthritis but has shown benefit in
patients with localized GPA
Nausea
Diarrhea
Mouth ulcers
Hair loss
Cytopenia
Liver dysfunction
Hypertension
Mycophenolate
mofetil
Induction or
maintenance
2–3 g per day Less effective than azathioprine as a
maintenance agent, nevertheless this
drug has a place in management of
ANCA vasculitis. As an induction agent it
appears to be as effective as
cyclophosphamide
Nausea
Diarrhea
Mouth ulcers
Hair loss
Cytopenia
Liver dysfunction
Co-trimoxazole Induction or
maintenance
960 mg twice a day or 960 mg 3× per
week if used in combination with
methotrexate
This simple antibiotic has
immunomodulatory effects in patients
with mild GPA and has been shown to
improve upper airways disease, usually
in combination with steroids. At the
reduced dose it can be used as
prophylaxis against pneumocystis
jirovecii in patients receiving other
immunosuppressive agents
Beware allergy to
sulfonamide
Nausea
Diarrhea
Cytopenia (avoid full dose
if combined with
methotrexate)
Azathioprine Induction
Maintenance
Usually given as 2 mg/kg/day for
maintenance but there is one report of
using high dose intravenous pulse
therapy with 1200 mg per month for
6 months in very resistant disease (13)
This is a common maintenance agent,
following successful induction therapy
with either cyclophosphamide or
rituximab
Nausea
Diarrhea
Mouth ulcers
Hair loss
Cytopenia
Liver dysfunction
Non-melanoma skin
tumors (advise sun
protection)
Ciclosporin Maintenance 2–4 mg/kg/day in two divided doses Less commonly used than other agents,
largely due to its nephrotoxicity
Nausea
Diarrhea
Gingival hyperplasia
Increased facial hair
Cytopenia
Renal dysfunction
Hypertension
(Continued)
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Table 1 | Continued
Drug Phase of
therapy
Dose Indication/comments Common adverse
effects
Gusperimus Relapse 0.5 mg/kg/day until neutropenia
develops or for up to 21 days repeated
every month for up to 6 months
Unlicensed in Europe, this
immunomodulator therapy has been
effective in relapsing GPA (14)
Well tolerated but limited
information because of very
limited use
Reversible and predictable neutropenia
Potential risk of sepsis
BIOLOGICAL IMMUNOSUPPRESSIVETHERAPIES USEDTOTREAT SYSTEMICVASCULITIS
Intravenous
immunoglobulin
(IVIG)
Induction 2 g/kg single dose or divided over
5 days is typical therapy for Kawasaki
disease (15). These doses are much
higher than those used for
immunodeficiency
Kawasaki disease is the main form of
vasculitis responding to IVIG, in
combination with high dose aspirin.
ANCA vasculitis will respond
temporarily, and this can be useful if
patients are also septic, because it is an
immunomodulating therapy. Check
serum IgA to avoid allergic reactions in
patients who are IgA deficient (because
there is usually some IgA
contamination). IVIG is prepared form
pooled human serum, typically from
thousands of donors. Viral screening of
IVIG is now highly effective (previous
IVIG therapy use has been associated
with hepatitis C transmission)
Potential risk of transmission of
viral infection if using infected
blood products
Allergic reaction in patients
who are IgA deficient (due to
expected levels of small
amounts of IgA in the
preparation)
Headaches, flushing, fever,
chills, fatigue, nausea, and
diarrhea are transient reactions
during infusions
Rituximab Induction or
maintenance
375 mg/m2 every week for 4 weeks or
1 g ×2 14 days apart are typical
induction regimens. Maintenance
therapy (typically 1 g single infusion)
can be given every 4–6 months
afterward
Increasingly used in place of
cyclophosphamide as induction therapy
at initial presentation or during relapse
for ANCA vasculitis
Infusion reactions neutropenia
hypogammaglobulinemia
Infections (including small risk
of progressive multifocal
leukoencephalopathy)
Potential for viral reactivation
(e.g., hepatitis B)
Development of other
autoimmune conditions
Tocilizumab Relapse 4 mg–8/kg per month intravenously or
162 mg sc per fortnight if <100 kg or
162 mg sc every week if ≥100 kg
Limited evidence for effectiveness in
large vessel vasculitis. A randomized
controlled trial in GCA is currently
underway (16)
Infection risk
Potential masking of evidence
of sepsis (by down regulating
production of CRP)
Increased lipid levels
Neutropenia
Liver dysfunction
Infusion reactions are rare
Mepolizumab Resistant
disease
Two different regimens are being
explored:
300 mg sc every 4 weeks
750 mg iv every 4 weeks
This interleukin five inhibitor is effective
in hypereosinophilic states and the iv
regimen has been shown to control
resistant cases of EGPA (17). A
randomized controlled trial using the sc
regimen is underway (http://clinicaltrials.
gov/show/NCT02020889)
Limited evidence available only
to date
No increase in toxicity
compared to placebo (e.g.,
fatigue, nausea)
Patients are typically given intense induction therapy followed by maintenance. Most patients will require additional therapy to manage comorbidity and limit drug
toxicity. Induction therapies can be repeated for relapse; however, it may be necessary to change the type of induction due to toxicity or poor initial response.
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development of targeted therapy against complement 5A (C5a),
which is currently being tested in clinical trials1. The involvement
by ANCA itself has led to development of specific B cell ablation
therapy using rituximab and now belimumab2. As newer under-
standing of disease mechanisms is revealed then more targets for
therapy will be identified or at least we will have better recogni-
tion of how we are affecting the underlying pathways with existing
therapies.
CANWE INDUCE REMISSION?
The aim of managing the patients with vasculitis is to induce
remission, which should be possible in the majority. However, this
is a clinical remission not a cure and the majority of patients will
relapse. We need to deliver treatment according to need without
exposing patients to unnecessary risk whilst ensuring the maxi-
mum benefit. Conventional measurements of clinical remission
are defined using disease activity scores, which are preferred to
any current serological marker for small vessel and medium ves-
sel vasculitis. In over 90% of patients with small vessel vasculitis,
remission should be achieved by 6 months (22) using standard
induction therapy. Further serial evaluation is important in order
to detect and treat relapses.
By contrast, in large vessel vasculitis, the induction of remission
is less easily documented. All the clinical symptoms and signs dis-
appear rapidly with steroid treatment; by contrast, it is not so clear
that we have adequately controlled disease at a sub-clinical level.
Imaging is emerging as an effective technology to define disease
activity. Unfortunately, it is expensive and can involve significant
radiation exposure. The best imaging technique available is 18 flu-
orodeoxyglucose positron emission tomography with co-localized
computerized tomography (FDG PET CT) to identify areas of
abnormal glucose uptake. However, this involves exposure to an
average of 14.4 mSv for females and 11.8 mSv for male patients
(34) per scan. Nevertheless, it is important to quantify the pres-
ence of sub-clinical disease to find ways of preventing end stage
ischemic complications or other vascular events such as throm-
bosis, dissection, and aneurysm. Non-invasive imaging protocols
using magnetic resonance scans or ultrasound are being developed
as ways of measuring change in disease state (35, 36).
HOW DOWE MEASURE REMISSION?
Serological measurements of disease activity are not reliable in sys-
temic vasculitis (37). ANCA testing is very useful for diagnosis, but
for subsequent follow up, levels can vary independently of future
disease activity (38).
The Birmingham Vasculitis Activity Score (BVAS) is the most
effective validated tool to document disease activity; it can be used
as to define remission, response to therapy and flare (37, 39, 40).
The BVAS consists of a list of typical features of active systemic
vasculitis related to each body system; each item is recorded as
present only if it is judged to be due to active vasculitis. This is
semi-subjective because items are derived from the patient his-
tory and physical examination and cannot always be confirmed
1http://clinicaltrials.gov/show/NCT01275287;
http://www.controlled-trials.com/ISRCTN53663626
2http://clinicaltrials.gov/show/NCT01663623
with more objective testing. However, the BVAS is valid, reli-
able, and widely used in clinical trials in vasculitis to define the
responsiveness to various agents including cyclophosphamide,
methotrexate, mycophenolate, intravenous immunoglobulin, and
rituximab. It is a valuable tool for the clinicians and strongly rec-
ommended as a routine part of disease management in small and
medium vessel vasculitis (40, 41). Other versions of BVAS have
been validated for use in individual forms of vasculitis, such as
the BVAS/Wegener’s granulomatosis, specifically for patients with
GPA (42).
The Vasculitis Damage Index (VDI) is used to assess the out-
come of vasculitis, by documenting the occurrence of damage as
a result of having a diagnosis of vasculitis (43, 44). VDI is rec-
ommended as a cumulative measure to define the effectiveness
of therapy (by limiting or preventing the accumulation of scar-
ring). The VDI is strongly related to mortality. The presence of
VDI levels of at least five points on a scale of 0–64 items (which
occurs in about a third of patients (45) when measured 6 months
from diagnosis) is associated with a much higher future mortality
(approximately sixfold higher) than patients with less than five
items of damage (46) 6 months from diagnosis.
WHAT DRUGS SHOULD WE USE?
Each patient’s management should be based on their diagnosis and
clinical state. Control of active vasculitis may be achieved using a
range of therapies, depending on how rapidly and aggressively the
treatment is required. The decision should be based on evidence,
but interpreted for the individual to minimize harm, taking into
account existing or likely co-morbidities. Some treatment pro-
tocols allow for this. For example, there are dose reductions for
the dose of cyclophosphamide in older persons, those with renal
impairment or with prior significant neutropenia (23).
The treatment protocol may need to be amended if unexpected
changes occur in clinical status, either as a result of toxicity or
if patients fail to respond to standard agents. Therapy should be
withheld until inter-current infection is treated, or escalated in
cases with poor initial response. Fundamental to these decisions
is the regular careful clinical evaluation of patients to detect these
changes. Table 1 summarizes the immunosuppressive agents com-
monly used as well as describing potential future therapies under
investigation.
IMMUNOSUPPRESSIVE THERAPIES
The main drug used is cyclophosphamide, cyclic nitrogen mus-
tard, phosphamide ester, first used as a chemotherapeutic agent in
the 1950s (47). Cyclophosphamide is a cytotoxic alkylating agent
capable of killing B cells and T-cells. It is life-saving in patients with
small and medium vessel vasculitis and is considered the drug of
choice for multi organ disease (22).
However, the toxicity has been considerable, when used as con-
tinuous daily oral therapy for up to 2.7 years, providing over 100 g
life-time exposure in some patients (48, 49), mainly due to its pre-
dicted cytotoxic effects on rapidly dividing normal cells. It can
cause reversible nausea, vomiting, diarrhea, and hair loss; per-
manent infertility and malignancy occur with increasing cumu-
lative doses, with an incidence of 5% at 10 years and 16% after
15 years (50). There is no absolute cut-off dose to avoid toxicity,
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but the recent British Society for Rheumatology guidelines for
management of ANCA-associated vasculitis recommend restrict-
ing total exposure to <25 g (41). Current cyclophosphamide pro-
tocols use a much lower cumulative dose and the bladder cancer
incidence is not increased (51). However, in a study of male fer-
tility risk in patients given cyclophosphamide for sarcoma (52), a
total dose of >7.5 g/m2 was associated with only a 10% chance of
recovery of spermatogenesis compared to 70% for those given less
than this dose. The use of short courses of high dose intravenous
cyclophosphamide is likely to be safer than continuous daily oral
therapy (53), chiefly due to the fact that the cumulative dose is
typically 30–50% less.
Cyclophosphamide is effective in reducing the mortality in
ANCA-associated vasculitis (22, 23). It can be given either as a
pulse intravenous high dose therapy 15 mg/kg every 2–3 weeks on
6–10 occasions or as a continuous daily oral therapy at 2 mg/kg/day
(54). The latter results in much higher cumulative dose of drug
over 6 months period and there is evidence of equivalent of
these two regimens; although the use of pulse cyclophosphamide
is associated with a higher relapse rate (23). For less aggres-
sive forms of vasculitis, there is a potential role for leflunomide
(24), methotrexate (23, 25, 55) or in one small series, high dose
intravenous azathioprine (13), and mycophenolate mofetil (56).
These agents are usually less toxic but also less effective than
cyclophosphamide.
For patients with large vessel vasculitis such as GCA or Takayasu
arteritis, the primary treatment is to suppress systemic inflamma-
tion with glucocorticoid therapy in order to prevent significant
vascular complications (such as loss of sight in GCA or aortic
aneurysm formation or stenosis or occlusion of peripheral arteries
in Takayasu arteritis. With better understanding of disease mech-
anisms, we might be able to use targeted therapies, perhaps even
avoiding the use of steroids, which otherwise carry very significant
risk of toxicity in over 80% (31).
There is some evidence for the effectiveness of TNF inhibition
in small vessel vasculitis (26), but concerns about long-term tox-
icity (27).In Takayasu arteritis (35), studies show improvement
but are limited to small numbers and there are no randomized
controlled trials. This is partly due to the problem of not having
adequate end points to demonstrate a potential treatment effect as
well as due to the rarity of the condition (57). Direct targeting of B
cells is an effective therapy for many patients; the response (64% in
complete remission by 6 months) is similar to that achieved with
cyclophosphamide (53% in complete remission by 6 months) for
a group of 197 patients with new or relapsing ANCA-associated
vasculitis; limited evidence suggests that in 102 patients with
relapsing disease previously responding to cyclophosphamide, rit-
uximab was more effective than cyclophosphamide (67 vs. 42% in
complete remission respectively, p= 0.01) (28–30).
For any form of B cell depletion therapy, it is logical to assume
that reconstitution of B cells after the end of treatment will lead
to recurrence (58), although this is disputed, with at least one
study demonstrating that disease relapse was independent of B
cell numbers (59). Nevertheless, maintenance rituximab substan-
tially reduces the risk of recurrence of disease from 73 to 12%
after 2 years follow up in retrospective cohort data (60). Another
retrospective observational study of 89 patients treated with ritux-
imab for ANCA-associated vasculitis (60) suggests that there was
additional protection against future relapse by using maintenance
azathioprine, methotrexate, or mycophenolate mofetil compared
to no additional immunosuppressive treatment [the hazard ratio
for relapse was 0.53 (95% CI 0.29–0.97) if a maintenance drug was
given].
DISCUSSION
The state of the art for therapy in vasculitis has improved, but
remains unsatisfactory until we can completely control or cure
the disease. We can prevent early mortality in multi-system vas-
culitis and have reduced the immediate effects of active vasculitis
on organ function. However, our aim is to further improve the
likelihood of survival and also the quality of life of those who sur-
vive, ensuring that we minimize disease activity and damage, drug
toxicity, and impairment of quality of life.
With better understanding of the pathogenesis of vasculi-
tis, we can target therapy against specific disease mechanisms.
Examples of these are rituximab in ANCA-associated vasculitis;
mepolizumab in eosinophilic granulomatosis with polyangiitis;
complement 5a inhibition in ANCA vasculitis; and potentially
Interleukin-6 (IL-6) inhibition with tocilizumab in large vessel
vasculitis.
We are helped in our management of the disease by earlier
diagnosis, so that treatment can be initiated before organ dam-
age is established in most cases. Whilst the ANCA test is overused
(61, 62), it has helped in earlier identification of patients with sys-
temic vasculitis (63). Greater awareness of vasculitis as a cause of
unexplained medical illness is leading to better case recognition.
Imaging of arteries in large vessel vasculitis may become estab-
lished as an early diagnostic test (64), which might change our
current management approach.
Better management of comorbidity, particularly management
of sepsis, control of hypertension, or management of renal failure
have changed the outcome and potentially allowed more aggressive
immunosuppression to be successful. However, in first 12 months
after diagnosis of ANCA vasculitis, episodes of acute sepsis are
now responsible for more deaths than vasculitis itself (49).
The role of glucocorticoids in vasculitis is being challenged.
Whereas, previously they have been used at high doses for pro-
longed periods, we recognize their harm, coupled by the benefit
from more specific therapy. We should see substantial reduction
in toxicity in the coming decade, as we use lower doses or even
steroid free regimens to control vasculitis.
Whilst the twentieth century has been dominated by use of
the therapies for vasculitis designed to treat other conditions [e.g.,
cancer and rheumatoid arthritis (23, 65, 66)], drugs are now been
designed specifically for vasculitis. We should see significant ben-
efits for our patients, but we need to ensure that we measure their
impact (for good and for harm). In the absence of reliable circu-
lating biomarkers we need to use structured clinical assessment to
document change in disease state in response to therapy. Devel-
opment of effective, prognostic biomarkers for vasculitis would
allow therapy to be targeted to disease mechanisms, tempered by
safety assessments to prevent untoward harm.
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